Multimeric CD20 Binding Molecules for Enhanced Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD20 monoclonal antibodies, such as rituximab, have limited efficacy in treating B-cell neoplasms due to resistance mechanisms like downregulation of CD20 on tumor cells, necessitating improved therapeutic agents with enhanced affinity and multivalency.
Innovation Solution
Development of pentameric and hexameric binding molecules comprising multiple bivalent binding units with CD20 antigen-binding domains, including IgM and IgA formats, which exhibit increased multivalency and recruit immune effector cells for enhanced cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rituximab (IgG format) is used as single agent therapy, then treatment is simple and well-tolerated, but clinical response rate is limited to 50% due to resistance mechanisms
Solution Approach 1:
The patent combines multiple binding units (two or more) into a single multimeric antibody molecule, merging the functions of multiple IgG antibodies into one entity. This increases avidity and potency while maintaining a single therapeutic agent structure, thereby improving clinical response rate without proportionally increasing complexity
Solution Approach 2:
The multimeric antibodies are designed to pre-form high-avidity binding structures before encountering target cells. The multivalent configuration ensures that when the antibody meets CD20-expressing cells, multiple binding sites are immediately available, overcoming resistance mechanisms that downregulate CD20 expression
2Power
If multimeric binding molecules (IgM/IgA formats) are used to increase multivalency, then potency and efficacy are improved, but molecular weight and size increase
Solution Approach 1:
The patent segments the multimeric antibody into distinct binding units, each with its own antigen-binding domains and constant regions. This segmentation allows the molecule to maintain high multivalency (increased power) while organizing the structure into modular units that may facilitate production and reduce the impact of increased molecular weight
3Reliability
If affinity and avidity are increased through multivalency, then response rates improve, but manufacturing and characterization become more difficult
Solution Approach 1:
The patent employs constant regions from natural immunoglobulin classes (IgM or IgA) that inherently provide multivalency and effector functions. By utilizing these universal, naturally occurring structural elements, the patent achieves high avidity and potency while leveraging well-understood biological systems that may simplify manufacturing compared to entirely novel multivalent structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These multimeric binding molecules demonstrate improved potency in inducing complement-mediated and T-cell-mediated killing of CD20-expressing cells, overcoming resistance mechanisms and achieving higher efficacy than monospecific IgG1 antibodies.
Implementation Method 1
Rituximab induces B-cell death primarily through complement-dependent lysis (CDC) and antibody dependent cellular toxicity (ADCC) effector mechanisms
Implementation Method 2
Rituximab induces B-cell death primarily through complement-dependent lysis (CDC) and antibody dependent cellular toxicity (ADCC) effector mechanisms
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement- mediated and T-cell-mediated killing of CD20-expressing cells.